National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

House Dust Mite Extract (Acarizax ®) for Allergic Asthma. HTA ID: 20016

House Dust Mite extract (Acarizax®) is indicated in adult patients (18-65 years) with HDM allergic asthma not well controlled by inhaled corticosteroids (ICS) and associated with mild to severe house dust mite allergic rhinitis. Diagnosis should be confirmed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE).

 

NCPE Assessment Process Complete
Rapid review commissioned 12/03/2020
Rapid review completed 30/04/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM extract (Acarizax ®) for allergic asthma compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 07/05/2020
Pre-submission consultation with Applicant 08/06/2020
Current status Awaiting Applicant Submission

The company has not submitted a HTA dossier to the NCPE; therefore the cost-effectiveness of the technology could not be proven.